ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 095

Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA)

Rotem Semo1, Rotem Tal 2, Tomas Dallos 3, Liora Harel 4, Lukas Plank 3 and Linda Wagner-Weiner 1, 1university of chicago, chicago, Illinois, 2schneider medical center, Ramat Gan, Israel, 3National Institute of Child Diseases, Bratislava, Slovakia, 4Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: granulomatosis with polyangiitis, payoderma gangrenosum, ulcerative skin lesion, Wegener's granulomatosis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose:  GPA is a form of anti-neutrophilic cytoplasmic antibody vasculitis affecting small to medium sized vessels and involves most commonly the kidneys and the respiratory tract.  Skin involvement can be seen in up to 50% of children with GPA, and is the presenting symptom in 7.7%.  Pyoderma gangrenosum (PG) is a rapidly progressive, sterile ulcerating neutrophilic dermatosis which most frequently affects the lower extremities.  PG-like ulceration rarely is described as a skin manifestation in GPA and very few cases have been reported previously in children.  Our aim was to identify and characterize GPA-related PG.  

Methods: A literature review through electronic database using the following keywords – “skin ulcer”, “pyoderma gangrenosum”, “granulomatosis with polyangiitis”, “Wegener’s granulomatosis” was conducted. Four pediatric GPA patients who had PG-like ulcerative lesions were identified. We assessed the clinical characteristics, serology, and response to treatment of these 4 cases, in addition to our 3 newly diagnosed cases.  We compared the distribution of PG-like ulcerative skin lesions in the 7 GPA patients with PG to those of children with PG and no GPA.

Results: Clinical characteristics of the 7 cases are presented in table I. The mean age at first symptom is 15 years with M:F ratio of 5:2. Five children had PG-like ulceration as their initial presentation; additional symptoms eventually led to their GPA diagnosis a mean of 10 months later (range 3 to 24 months). In 2 cases, proteinase 3 (PR3) was negative when first tested, but converted to positive on repeat evaluation when systemic symptoms emerged. All patients eventually had a positive PR3.  The ulcerative PG-like lesions initially manifested as purpura, nodule or acne in 4 patients. All 7 patients had primarily facial lesions, compared to only 3.9% of 170 pediatric patients with PG which are described in the literature. Our patients also had chest and back involvement.  Four of the seven skin biopsies showed granulomatous inflammation, however 2 of these were noted only on reassessment by dermatopathologists after the diagnosis of GPA was made.  Six of seven patients had upper respiratory tract involvement.  Three had pulmonary and 4 had renal involvement. None of the 7 patients responded to treatment with antibiotics or medications commonly used to manage PG, including corticosteroids and cyclosporine. The five patients who received rituximab all had excellent responses, including one who had failed cyclophosphamide.  Pre- and post-treatment images of patients 1 and 2 can be seen in Fig I. Histology of an ulcerative skin lesion of patient 2 can be seen in Fig II.

Conclusion: PG-like ulceration is a unique and rare presentation of GPA which sometimes precedes the classic systemic GPA symptoms. The predominance of facial ulcer, granulomatous inflammation on skin biopsy and lack of response to PG treatments are more common in GPA-associated PG. Our review suggests that treatment of GPA with rituximab may be needed to improve the skin lesions.  Recognizing that PG-like ulcerations can occur in GPA may result in a timely diagnosis and appropriate treatment which can help improve prognosis.

Table 1: Demographic and clinical characteristics of patients with GPA and PG. Abbreviation: M : male; F : female; PR3 ab: proteinase 3 antibody; N/A : not available; ABX: antibiotic; CS: corticosteroids; CYC: cyclophosphamide; MMF: mycophenolate mofetil: PLEX: plasma exchange

Fig IA – images of temporal lesions pre and post treatment of a 15 yrs old female with GPA, Fig IIB – images


Disclosure: R. Semo, None; R. Tal, None; T. Dallos, None; L. Harel, None; L. Plank, None; L. Wagner-Weiner, None.

To cite this abstract in AMA style:

Semo R, Tal R, Dallos T, Harel L, Plank L, Wagner-Weiner L. Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/pyoderma-gangrenosum-ulceration-as-a-presenting-feature-of-pediatric-granulomatosis-with-polyangiitis-gpa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pyoderma-gangrenosum-ulceration-as-a-presenting-feature-of-pediatric-granulomatosis-with-polyangiitis-gpa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology